12750 HIGH BLUFF DRIVE SUITE 475, SAN DIEGO, CA
Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
Announces Availability of Annual Report on Form 20-F Through Company Website
Material disclosure
Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
Announces Proposed Underwritten Public Offering of American Depositary Shares
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence
Submission Upload